264 related articles for article (PubMed ID: 21876211)
1. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium.
Chang P; Orabi B; Deranieh RM; Dham M; Hoeller O; Shimshoni JA; Yagen B; Bialer M; Greenberg ML; Walker MC; Williams RS
Dis Model Mech; 2012 Jan; 5(1):115-24. PubMed ID: 21876211
[TBL] [Abstract][Full Text] [Related]
2. Diacylglycerol kinase (DGKA) regulates the effect of the epilepsy and bipolar disorder treatment valproic acid in
Kelly E; Sharma D; Wilkinson CJ; Williams RSB
Dis Model Mech; 2018 Aug; 11(9):. PubMed ID: 30135067
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid.
Xu X; Müller-Taubenberger A; Adley KE; Pawolleck N; Lee VW; Wiedemann C; Sihra TS; Maniak M; Jin T; Williams RS
Eukaryot Cell; 2007 Jun; 6(6):899-906. PubMed ID: 17435006
[TBL] [Abstract][Full Text] [Related]
4. Conserved valproic-acid-induced lipid droplet formation in Dictyostelium and human hepatocytes identifies structurally active compounds.
Elphick LM; Pawolleck N; Guschina IA; Chaieb L; Eikel D; Nau H; Harwood JL; Plant NJ; Williams RS
Dis Model Mech; 2012 Mar; 5(2):231-40. PubMed ID: 22003123
[TBL] [Abstract][Full Text] [Related]
5. Structure-function studies for the panacea, valproic acid.
Terbach N; Williams RS
Biochem Soc Trans; 2009 Oct; 37(Pt 5):1126-32. PubMed ID: 19754465
[TBL] [Abstract][Full Text] [Related]
6. New experimental therapies for status epilepticus in preclinical development.
Walker MC; Williams RS
Epilepsy Behav; 2015 Aug; 49():290-3. PubMed ID: 26189787
[TBL] [Abstract][Full Text] [Related]
7. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior.
Shimshoni JA; Dalton EC; Jenkins A; Eyal S; Ewan K; Williams RS; Pessah N; Yagen B; Harwood AJ; Bialer M
Mol Pharmacol; 2007 Mar; 71(3):884-92. PubMed ID: 17167030
[TBL] [Abstract][Full Text] [Related]
8. Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model Dictyostelium.
Terbach N; Shah R; Kelemen R; Klein PS; Gordienko D; Brown NA; Wilkinson CJ; Williams RS
J Cell Sci; 2011 Jul; 124(Pt 13):2267-76. PubMed ID: 21652627
[TBL] [Abstract][Full Text] [Related]
9. Quantifying in vivo phosphoinositide turnover in chemotactically competent Dictyostelium cells.
Pawolleck N; Williams RS
Methods Mol Biol; 2009; 571():283-90. PubMed ID: 19763974
[TBL] [Abstract][Full Text] [Related]
10. Valproate decreases inositol biosynthesis.
Shaltiel G; Shamir A; Shapiro J; Ding D; Dalton E; Bialer M; Harwood AJ; Belmaker RH; Greenberg ML; Agam G
Biol Psychiatry; 2004 Dec; 56(11):868-74. PubMed ID: 15576064
[TBL] [Abstract][Full Text] [Related]
11. Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure.
Eickholt BJ; Towers GJ; Ryves WJ; Eikel D; Adley K; Ylinen LM; Chadborn NH; Harwood AJ; Nau H; Williams RS
Mol Pharmacol; 2005 May; 67(5):1426-33. PubMed ID: 15687223
[TBL] [Abstract][Full Text] [Related]
12. The mood stabilizer valproate inhibits both inositol- and diacylglycerol-signaling pathways in Caenorhabditis elegans.
Tokuoka SM; Saiardi A; Nurrish SJ
Mol Biol Cell; 2008 May; 19(5):2241-50. PubMed ID: 18287529
[TBL] [Abstract][Full Text] [Related]
13. Trimetazidine potentiates the antiepileptic activity and ameliorates the metabolic changes associated with pentylenetetrazole kindling in rats treated with valproic acid.
Sedky AA; El Serafy OMH; Hassan OA; Abdel-Kawy HS; Hasanin AH; Raafat MH
Can J Physiol Pharmacol; 2017 Jun; 95(6):686-696. PubMed ID: 28177664
[TBL] [Abstract][Full Text] [Related]
14. Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy.
De Caro C; Leo A; Nesci V; Ghelardini C; di Cesare Mannelli L; Striano P; Avagliano C; Calignano A; Mainardi P; Constanti A; Citraro R; De Sarro G; Russo E
Sci Rep; 2019 Sep; 9(1):13983. PubMed ID: 31562378
[TBL] [Abstract][Full Text] [Related]
15. Seizure control by ketogenic diet-associated medium chain fatty acids.
Chang P; Terbach N; Plant N; Chen PE; Walker MC; Williams RS
Neuropharmacology; 2013 Jun; 69():105-14. PubMed ID: 23177536
[TBL] [Abstract][Full Text] [Related]
16. Valproate: past, present, and future.
Johannessen CU; Johannessen SI
CNS Drug Rev; 2003; 9(2):199-216. PubMed ID: 12847559
[TBL] [Abstract][Full Text] [Related]
17. Valproic Acid: second generation.
Bialer M; Yagen B
Neurotherapeutics; 2007 Jan; 4(1):130-7. PubMed ID: 17199028
[TBL] [Abstract][Full Text] [Related]
18. A Long-Term Treatment with Arachidonyl-2'-Chloroethylamide Combined with Valproate Increases Neurogenesis in a Mouse Pilocarpine Model of Epilepsy.
Andres-Mach M; Zagaja M; Haratym-Maj A; Rola R; Maj M; Haratym J; Dudra-Jastrzębska M; Łuszczki JJ
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28441341
[TBL] [Abstract][Full Text] [Related]
19. Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
van Vliet EA; Edelbroek PM; Gorter JA
Epilepsia; 2010 Mar; 51(3):362-70. PubMed ID: 19674045
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP.
Chang P; Chandler KE; Williams RS; Walker MC
Epilepsia; 2010 Aug; 51(8):1533-42. PubMed ID: 20002144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
